Dashboard
Manage Tickers

SNYSanofi

Nasdaq sanofi.com


$ 48.85 $ 0.32 (0.66 %)    

Wednesday, 03-Jul-2024 12:59:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 48.86
$ 48.76
$ 0.00 x 0
$ 49.98 x 100
$ 48.52 - $ 48.93
$ 40.90 - $ 53.45
1,140,137
na
61.39B
$ 0.58
$ 10.28
TBD
na
na ($ 0.08)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

sanofi-ceo-says-talking-to-private-equity-for-sale-of-consumer-arm
Sanofi CEO Says Talking To Private Equity ...
07/03/2024 15:59:43

- Bloomberg

europe-approves-sanofiregenerons-dupixent-for-smokers-lungs-a-month-after-us-fda-asks-for-data
Europe Approves Sanofi/Regeneron's Dupixen...
07/03/2024 12:55:42

EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised ...

heartburn-drug-zantac-litigation-gsk-and-other-pharma-giants-face-trial-over-cancer-claims
Heartburn Drug Zantac Litigation: GSK And ...
07/02/2024 12:39:03

A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to...

sanofi-nears-decision-on-16b-upgrade-for-frankfurt-insulin-plant
Sanofi Nears Decision on $1.6B Upgrade For...
07/01/2024 15:13:28

Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany'...

sanofis-frexalimab-phase-2-data-shows-41-reduction-in-key-biomarker-of-nerve-cell-damage-in-relapsing-ms-high-dose-arm-demonstrates-significant-drop-in-plasma-neurofilament-light-chain-levels-after-48-weeks-supports-potential-as-high-efficacy-disease-modifying-treatment-phase-3-studies-underway
Sanofi's Frexalimab Phase 2 Data Shows 41%...
06/28/2024 15:41:36

Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MSFrexalimab high-dose arm obse...

Core News & Articles
CDC's ACIP Unanimously Votes To Add Merck ...
06/27/2024 19:40:39

- Reuters

first-inhaled-copd-therapy-in-over-2-decades---fda-approves-verona-pharmas-first-commercial-product
First Inhaled COPD Therapy In Over 2 Decad...
06/27/2024 13:49:19

The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary dis...

Core News & Articles
Vigil Neuroscience Secures $40M from Sanof...
06/27/2024 06:59:38

Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f...

Core News & Articles
Regeneron, Sanofi Present Phase 3 Trial Fo...
06/26/2024 21:34:07

The trial showed a greater proportion of those receiving weight-tiered higher dose Dupixent experienced significant improvement...

sanofi-looks-to-sell-20b-icy-hot-division-likely-bidders-include-advent-pai-partners-blackstone-cvc
Sanofi Looks To Sell $20B Icy Hot Division...
06/26/2024 13:16:58

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

tuesday-sanofi-announced-riliprubart-one-year-follow-up-from-phase-2-study-showed-efficacy-and-safety-and-rapid-and-durable-reduction-of-key-biomarkers-including-those-associated-with-classical-complement-pathway-and-nerve-cell-damage
Tuesday Sanofi Announced Riliprubart One-y...
06/26/2024 10:49:20

https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-25-20-30-00-2904145

sanofi-seeks-bids-for-20b-consumer-arm-by-mid-july-advent-pai-among-top-suitors-blackstone-cdr-cvc-and-tpg-also-interested
Sanofi Seeks Bids For $20B Consumer Arm By...
06/25/2024 16:53:31

- Bloomberg Citing Sources

sanofi-to-present-altuviiios-long-term-efficacy-and-fitusirans-prophylaxis-potential-at-isth
Sanofi To Present ALTUVIIIO's Long-Term Ef...
06/21/2024 05:42:03

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the...

industry-groups-back-gsks-effort-to-halt-70000-lawsuits-associated-with-heartburn-drug-zantac-caused-cancer
Industry Groups Back GSK's Effort To Halt ...
06/20/2024 18:03:20

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threat...

sanofi-and-biovac-announce-partnership-to-manufacture-inactivated-polio-vaccines-in-africa-biovac-becomes-first-african-producer-of-ipv-aims-to-serve-over-40-african-countries-and-supports-africa-cdcs-goal-for-60-local-vaccine-production-by-2040
Sanofi and Biovac Announce Partnership to ...
06/20/2024 12:08:35

Core News & Articles
Innate Pharma And Sanofi's Blood Cancer Tr...
06/17/2024 06:20:19

SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a jo...

Core News & Articles
World Health Organization Chief Says At Th...
06/12/2024 14:40:10

-Reuters

Core News & Articles
Regeneron, Sanofi Report FDA Approval Of K...
06/11/2024 11:02:06

sanofi-highlights-data-from-blood-cancer-drug-sarclisa-in-new-diagnosed-multiple-myeloma-patients
Sanofi Highlights Data From Blood Cancer D...
06/04/2024 19:18:18

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, t...

sanofis-imroz-phase-3-study-shows-sarclisa-with-vrd-reduces-risk-of-disease-progression-or-death-by-40-in-newly-diagnosed-transplant-ineligible-multiple-myeloma-first-global-phase-3-study-of-anti-cd38-with-vrd-to-improve-pfs-and-show-deep-responses-results-presented-at-asco-and-published-in-nejm
Sanofi's IMROZ Phase 3 Study Shows Sarclis...
06/03/2024 20:21:33

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)